Chapter 3. Detection, Evaluation, and Treatment Goals for Lipid Disorders in Adults

  1. Peter P. Toth M.D., PH.D. Director of Preventive Cardiology Chief of Medicine Clinical Associate Professor1,2,3,4 and
  2. Kevin C. Maki PH.D. President Chief Science Officer5

Published Online: 1 OCT 2008

DOI: 10.1002/9780470696873.ch3

Practical Lipid Management: Concepts and Controversies

Practical Lipid Management: Concepts and Controversies

How to Cite

Toth, P. P. and Maki, K. C. (2008) Detection, Evaluation, and Treatment Goals for Lipid Disorders in Adults , in Practical Lipid Management: Concepts and Controversies, John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470696873.ch3

Author Information

  1. 1

    Sterling Rock Falls Clinic, Ltd., USA

  2. 2

    CGH Medical Center Sterling, Illinois, USA

  3. 3

    Departments of Family and Community Medicine, University of Illinois College of Medicine Peoria, Illinois, USA

  4. 4

    Southern Illinois University School of Medicine, Springfield, Illinois, USA

  5. 5

    Provident Clinical Research & Consulting, Inc., Glen Ellyn, Illinois and Bloomington, Indiana, USA

Publication History

  1. Published Online: 1 OCT 2008
  2. Published Print: 17 OCT 2008

ISBN Information

Print ISBN: 9780470056905

Online ISBN: 9780470696873

SEARCH

Keywords:

  • National Cholesterol Education Program Adult Treatment Panel (NCEP ATP);
  • coronary heart disease (CHD) risk category;
  • dyslipidemia screening;
  • very low-density lipoprotein cholesterol (VLDL-C);
  • risk stratification;
  • detection, evaluation, and treatment goals;
  • Framingham risk score (FRS);
  • triglycerides and HDL-C therapy targets

Summary

This chapter contains sections titled:

  • Matching Aggressiveness of Treatment to Absolute Risk

  • Screening for Dyslipidemias

  • Risk Stratification

  • Steps in the Risk Stratification Process – Major Risk Categories

  • Tips for Calculating the Framingham Risk Score

  • Subcategories for Consideration of More Aggressive Optional Treatment Goals

  • Very High Risk Patients, Optional LDL-C Goal <70 mg dl−1

  • Moderately High Risk Patients, OPTIONAL LDL-C Goal <100 mg dl−1

  • Treatment Goals for Patients with Elevated Triglycerides

  • Triglycerides and HDL-C as Targets for Therapy

  • Controversy: Should Treatment Guidelines Include Targets for the Total/HDL Cholesterol Ratio?